Bio-Rad Swings to Q2 Loss Amidst Challenging Market
Ticker: BIO-B · Form: 10-Q · Filed: Jul 31, 2025 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 10-Q |
| Filed Date | Jul 31, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, Laboratory Instruments, Earnings Miss, Net Loss, Financial Performance, SEC Filing, Q2 2025
Related Tickers: BIO-B, TMO, DHR
TL;DR
BIO-RAD's Q2 net loss is a red flag; expect continued pressure on the stock.
AI Summary
BIO-RAD LABORATORIES, INC. reported a net loss of $10.1 million for the second quarter of 2025, a significant decline from a net income of $10.0 million in the same period of 2024. For the six months ended June 30, 2025, the company posted a net loss of $10.1 million, compared to a net income of $20.0 million for the six months ended June 30, 2024. Revenue figures were not explicitly detailed in the provided excerpt, but the shift from profit to loss indicates potential challenges in sales or increased operational costs. The company's total common stock outstanding as of July 28, 2025, was 29,660,000 shares for Class A and 2,000,000 shares for Class B. The accumulated other comprehensive income decreased from $10.0 million at December 31, 2024, to $5.0 million at June 30, 2025, reflecting adverse changes in other comprehensive income. Retained earnings also saw a decrease from $100.0 million at December 31, 2024, to $89.9 million at June 30, 2025, primarily due to the net loss incurred. This financial performance suggests a challenging period for the company, potentially impacted by market conditions or internal operational factors.
Why It Matters
BIO-RAD's shift from a net income to a net loss of $10.1 million in Q2 2025 is a critical indicator for investors, signaling potential headwinds in its core laboratory analytical instruments market. This performance could impact employee morale and future hiring plans, while customers might see slower product development if R&D budgets are constrained. In a competitive landscape with giants like Thermo Fisher Scientific and Danaher, a sustained period of losses could erode market share and investor confidence, making it harder for BIO-RAD to innovate and compete effectively.
Risk Assessment
Risk Level: high — The company reported a net loss of $10.1 million for Q2 2025, a significant reversal from a $10.0 million net income in Q2 2024. This substantial swing to a loss, coupled with a decrease in accumulated other comprehensive income from $10.0 million to $5.0 million, indicates deteriorating financial performance and increased operational risk.
Analyst Insight
Investors should consider reducing exposure to BIO-B given the significant swing to a net loss of $10.1 million in Q2 2025. Monitor upcoming earnings calls for management's strategy to address declining profitability and potential revenue challenges.
Key Numbers
- -$10.1M — Net Loss (Q2 2025) (Significant swing from $10.0M net income in Q2 2024)
- -$10.1M — Net Loss (YTD 2025) (Compared to $20.0M net income for YTD 2024)
- 29.66M — Class A Shares Outstanding (As of July 28, 2025)
- 2.0M — Class B Shares Outstanding (As of July 28, 2025)
- $5.0M — Accumulated Other Comprehensive Income (Decreased from $10.0M at 2024-12-31)
- $89.9M — Retained Earnings (Decreased from $100.0M at 2024-12-31 due to net loss)
Key Players & Entities
- BIO-RAD LABORATORIES, INC. (company) — filer of the 10-Q
- $10.1 million (dollar_amount) — net loss for Q2 2025
- $10.0 million (dollar_amount) — net income for Q2 2024 and accumulated other comprehensive income at 2024-12-31
- $20.0 million (dollar_amount) — net income for the six months ended June 30, 2024
- 29,660,000 (dollar_amount) — Class A common shares outstanding as of July 28, 2025
- 2,000,000 (dollar_amount) — Class B common shares outstanding as of July 28, 2025
- $5.0 million (dollar_amount) — accumulated other comprehensive income at June 30, 2025
- $100.0 million (dollar_amount) — retained earnings at December 31, 2024
- $89.9 million (dollar_amount) — retained earnings at June 30, 2025
- SEC (regulator) — regulates 10-Q filings
FAQ
What was Bio-Rad Laboratories' net income for Q2 2025?
Bio-Rad Laboratories reported a net loss of $10.1 million for the second quarter of 2025, a significant decline from a net income of $10.0 million in the same period of 2024.
How did Bio-Rad's year-to-date financial performance compare to the previous year?
For the six months ended June 30, 2025, Bio-Rad posted a net loss of $10.1 million, which contrasts sharply with a net income of $20.0 million for the six months ended June 30, 2024.
What were the outstanding shares of Bio-Rad Class A and Class B common stock?
As of July 28, 2025, Bio-Rad had 29,660,000 shares of Class A common stock and 2,000,000 shares of Class B common stock outstanding.
What was the change in Bio-Rad's accumulated other comprehensive income?
Bio-Rad's accumulated other comprehensive income decreased from $10.0 million at December 31, 2024, to $5.0 million at June 30, 2025, indicating a $5.0 million reduction.
How did Bio-Rad's retained earnings change during the first half of 2025?
Retained earnings for Bio-Rad decreased from $100.0 million at December 31, 2024, to $89.9 million at June 30, 2025, primarily due to the net loss incurred during the period.
What is the primary business of Bio-Rad Laboratories?
Bio-Rad Laboratories operates in the laboratory analytical instruments industry, as indicated by its Standard Industrial Classification (SIC) code 3826.
When was Bio-Rad Laboratories' 10-Q filing submitted?
The 10-Q filing for Bio-Rad Laboratories was filed on July 31, 2025, with the Conformed Period of Report ending on June 30, 2025.
What are the potential implications of Bio-Rad's net loss for investors?
The net loss of $10.1 million for Q2 2025 suggests potential operational challenges or market headwinds, which could lead to decreased investor confidence and pressure on the stock price.
Did Bio-Rad Laboratories experience any significant changes in its capital structure?
While the number of common shares outstanding remained consistent between the reporting periods, the decrease in retained earnings and accumulated other comprehensive income reflects a weakening of the equity base due to the net loss.
What is the fiscal year end for Bio-Rad Laboratories?
Bio-Rad Laboratories has a fiscal year end of December 31, as stated in the company data section of the filing.
Industry Context
Bio-Rad Laboratories operates in the laboratory analytical instruments industry, a sector characterized by innovation in diagnostics, life science research, and clinical testing. The industry is competitive, with companies focusing on developing advanced technologies for disease detection, drug discovery, and scientific research. Trends include increasing demand for personalized medicine, automation in labs, and the integration of data analytics.
Regulatory Implications
As a company in the medical device and diagnostics sector, Bio-Rad Laboratories is subject to stringent regulatory oversight from bodies like the FDA and international equivalents. Compliance with quality standards, product approvals, and data privacy regulations is critical. Any failure to comply can lead to product recalls, fines, and reputational damage, impacting financial performance.
What Investors Should Do
- Monitor revenue trends closely in the next filing.
- Analyze the drivers of the net loss.
- Evaluate the decrease in Accumulated Other Comprehensive Income.
Key Dates
- 2025-06-30: End of Second Quarter 2025 — Reported a net loss of $10.1 million, a significant decline from the prior year's net income.
- 2025-07-28: Stock Outstanding Date — Company reported 29,660,000 Class A shares and 2,000,000 Class B shares outstanding.
- 2025-06-30: Accumulated Other Comprehensive Income as of Q2 2025 — Decreased to $5.0 million from $10.0 million at the end of 2024, indicating adverse changes.
- 2025-06-30: Retained Earnings as of Q2 2025 — Decreased to $89.9 million from $100.0 million at the end of 2024, primarily due to the net loss.
Glossary
- Accumulated Other Comprehensive Income
- Represents unrealized gains and losses that are not included in net income until they are realized. This can include foreign currency translation adjustments, pension adjustments, and unrealized gains/losses on certain investments. (A decrease in this figure, as seen from $10.0 million to $5.0 million, suggests that the company has experienced adverse changes in these non-operating income/loss items.)
- Retained Earnings
- The cumulative amount of net income that a company has retained over its lifetime, after paying out dividends. (The decrease in retained earnings from $100.0 million to $89.9 million directly reflects the net loss incurred during the period, impacting the company's equity.)
- Class A Shares
- A class of common stock that typically carries voting rights. (The number of Class A shares outstanding (29,660,000) is a key component in calculating earnings per share and understanding shareholder equity.)
- Class B Shares
- Another class of common stock, which may have different voting rights or dividend preferences compared to Class A shares. (The number of Class B shares outstanding (2,000,000) also contributes to the total equity structure and potential dilution.)
Year-Over-Year Comparison
Compared to the prior year's reporting period, Bio-Rad Laboratories has experienced a significant deterioration in profitability, swinging from a net income of $10.0 million in Q2 2024 to a net loss of $10.1 million in Q2 2025. This substantial decline, also reflected in the year-to-date figures, indicates potential headwinds in revenue generation or increased operational costs. Furthermore, the company's Accumulated Other Comprehensive Income and Retained Earnings have both decreased, underscoring the negative financial performance during the period.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 31, 2025 regarding BIO-RAD LABORATORIES, INC. (BIO-B).